Protagonist Therapeutics, Inc Interest Receivable, Current
Protagonist Therapeutics, Inc (PTGX) had Interest Receivable, Current of $2.86 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:InterestReceivableCurrent · last filed 2026-08-05
- 2026-06-30: Interest Receivable, Current $2.86M.
- 2026-03-31: Interest Receivable, Current $3.46M.
- 2025-12-31: Interest Receivable, Current $4.37M.
- 2025-09-30: Interest Receivable, Current $4.55M.
| Period end | Interest Receivable, Current |
|---|---|
| 2026-06-30 | $2.86M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.46M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $4.37M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $4.55M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.52M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.26M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $3.24M 10-K · filed 2026-02-25 |
| 2023-12-31 | $256.00K 10-K · filed 2025-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |